Center for Emerging Diseases, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, U P, India.
Expert Opin Ther Pat. 2020 Jun;30(6):467-480. doi: 10.1080/13543776.2020.1751817. Epub 2020 Apr 17.
: Chikungunya virus (CHIKV), a reemerging human arthropod borne virus, can causes global epidemic outbreaks and has become a serious health concern due to the unavailability of any antiviral therapy/vaccine. Extensive research has been conducted to target different proteins from CHIKV to curtail the spread of virus.: This review provides an overview of the granted patents including the current status of antiviral strategies targeting CHIKV.: Under the current scenario, potential molecules and different approaches have been utilized to suppress CHIKV infection. MV-CHIKV and VRC-CHKVLP059-00-VP vaccine candidates have successfully completed phase I clinical trials and ribavirin (inhibitor) has shown significant inhibition of CHIKV replication and could be the most promising candidates. The drug resistance and toxicity can be modulated by using the inhibitors/drugs in combination. Moreover, nanoparticle formulations can improve the efficacy and bioavailability of drugs.
基孔肯雅病毒（CHIKV）是一种重新出现的人类虫媒病毒，能够引起全球流行疫情爆发，由于没有任何抗病毒疗法/疫苗，因此成为严重的健康问题。已经进行了广泛的研究，针对 CHIKV 的不同蛋白来遏制病毒的传播。
本综述概述了已授权的专利，包括针对 CHIKV 的抗病毒策略的现状。
在当前情况下，已经利用潜在分子和不同方法来抑制 CHIKV 感染。MV-CHIKV 和 VRC-CHKVLP059-00-VP 疫苗候选物已成功完成 I 期临床试验，利巴韦林（抑制剂）已显示出对 CHIKV 复制的显著抑制作用，可能是最有前途的候选物。通过抑制剂/药物联合使用，可以调节药物的耐药性和毒性。此外，纳米颗粒制剂可以提高药物的疗效和生物利用度。
